Endonovo Therapeutics Inc. (ENDV) Revenues Up 153% in Q3, SofPulse® Already Successfully in Use at Over 30 Medical Facilities Nationwide
Revenues for the nine months ended September 30, 2019 also increased 293% to $161,720 Company is selling SofPulse(R), its noninvasive Electroceutical(R) therapeutic device, in 7 hospitals, 11 surgery centers and 14 other medical facilities The device is currently under evaluation in 112 other healthcare facilities and Endonovo expects to become a premier supplier to hospitals nationwide for post-operative pain management Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc. (OTCQB: ENDV) reported its financial results for the third quarter of 2019 via a press release issued on November 19, 2019 (http://ibn.fm/OfcoV). According to the announcement, Endonovo’s revenues increased by 153% to $54,039…